Test-retest Evaluation of [18F]F-AraG PET
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This pilot study aims to evaluate the test-retest variability of \[18F\]F-AraG-PET imaging in patients with advanced NSCLC tumors. The main objectives of the study are to quantify the uptake of \[18F\]F-AraG in tumors and lymphoid tissue in two consecutive scans spaced not longer than 7 days apart from each other to estimate the magnitude of physiologic and measurement variability. To explore these objectives, eligible subjects will undergo two \[18F\]F-AraG PET/CT scans within 7 days of each other prior to receiving treatment. This study is a single-site, open-label, non-randomized, single-arm pilot trial. Patients and care providers will not be blinded to any part of the study.
Sponsor: CellSight Technologies, Inc.
You may qualify if…
- ✓ 1. Patients (\>18 years old) with a histologically confirmed NSCLC and a candidate to receive immunotherapy as monotherapy or as combination therapy for advanced/metastatic disease.
- ✓ 2. Measurable disease.
- ✓ 3. ECOG performance status of 0, 1 or 2.
You may not qualify if…
- ✕ 1. Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives.
- ✕ 2. Pregnant women or nursing mothers.
- ✕ 3. Patients with severe claustrophobia.
Where it's recruiting
Iowa City
Source: ClinicalTrials.gov · NCT06084806 · last updated 2024-10-24